Vivacitas Oncology and IAG Partner to Integrate Novel Imaging Markers in the Development of AR-67 in Recurrent Glioblastoma Patients – IAG
[WALNUT CREEK, CALIFORNIA, US AND LONDON, UK, May 3, 2021] – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a clinical stage biopharmaceutical company focused on tough to treat cancers, and Image Analysis Group (“IAG”), a leading global medical imaging company, are collaborating to apply Artificial Intelligence (AI) technology and advanced imaging strategies to further the […]
DSS Expands its Healthcare Segment through Investment in Vivacitas Oncology
DSS Expands its Healthcare Segment through Investment in Vivacitas Oncology ROCHESTER, N.Y., April 08, 2021 (GLOBE NEWSWIRE) — Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, today announced DSS Biomedical International, […]
Theralink® Technologies Achieves California CLIA Clinical and Public Health Certification
Denver, Colorado – March 29th, 2021 – Theralink Technologies, Inc. (OTC: OBMP), a precision medicine and molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced that the Company has received Clinical and Public Health License from the State of California for its Golden, Colorado laboratory, effective March […]
Theralink® Technologies Moves Closer Toward Changing the Standard of Care for All Women Newly Diagnosed with HER2+ Breast Cancer
George Mason University and Rutgers Cancer Institute of New Jersey Name Theralink Technologies as the Commercial Provider of Critical Assay DENVER – February 22, 2021 – In a recent announcement by Rutgers Cancer Institute of New Jersey and the Center for Applied Proteomics and Molecular Medicine at George Mason University (CAPMM), Theralink Technologies (OTC: OBMP) […]